Overcoming drug resistance with specific nano scales to targeted therapy: Focused on metastatic cancers
- 21 January 2024
- journal article
- review article
- Published by Elsevier in Pathology - Research and Practice
- Vol. 255, 155137
Abstract
No abstract availableKeywords
Funding Information
- Shaqra University
This publication has 110 references indexed in Scilit:
- Role of Glutathione in Cancer Progression and ChemoresistanceOxidative Medicine and Cellular Longevity, 2013
- Multidrug Resistance–Linked Gene Signature Predicts Overall Survival of Patients with Primary Ovarian Serous CarcinomaClinical Cancer Research, 2012
- Genetic heterogeneity and cancer drug resistanceThe Lancet Oncology, 2012
- Cancer immunotherapy via dendritic cellsNature Reviews Cancer, 2012
- Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencingNature, 2012
- Membrane vesicles, current state-of-the-art: emerging role of extracellular vesiclesCellular and Molecular Life Sciences, 2011
- Phase I/II and Phase II Studies of Targeted Gene Delivery In Vivo: Intravenous Rexin-G for Chemotherapy-resistant Sarcoma and OsteosarcomaMolecular Therapy, 2009
- Magnetic nanoparticles for theragnosticsAdvanced Drug Delivery Reviews, 2009
- Drug delivery and nanoparticles: Applications and hazardsInternational Journal of Nanomedicine, 2008
- Multidrug resistance in cancer: role of ATP–dependent transportersNature Reviews Cancer, 2002